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Objectives: To investigate efﬁcacy and safety of long-term daily oral administration
of a water-soluble new chemical entity of vitamin E (vE)-tocofersolan (d-a-
tocopherol-polyethyleneglycol-1000) in pediatric CF patients.
Methods: A multicentre open-label study. Patients were supplemented with vE at
a mean (SD) dose of 10.4 (4.3)mg/kg/d and switched to tocofersolan at a dose of
6.7mg/kg/d (d-a-tocopherol being 1.5 times more potent). Efﬁcacy was monitored
by tocopherolemia (T), ratio of vE/lipids (T/L) at baseline, months 3 and 6. Safety
analysis combined adverse events (AE), vital signs, laboratory data.
Results: 32 children were included (18 M, 14 F, median age: 65.7 months) and
29 completed the study. Compliance was excellent. At 3 and 6 months, T, T/L
did not change signiﬁcantly from baseline (under liposoluble or water-miscible
preparations of dl-alpha-tocopherol) and remained within respective normal ranges
(12−35mmol/L and >0.6mg/g). Five serious AE (SAE) were recorded (bronchi-
tis (2), hypotrophy, moderate hair loss, behaviour disorders). The relationship
between tocofersolan and hair loss, which completely recovered after cessation
of the drug, is unknown, yet all other SAE were unrelated to the study drug.
Conclusion: Efﬁcacy of tocofersolan was consistently maintained over time with
normal indices of T. This is in accordance with pharmacokinetics in CF demonstrat-
ing similar oral absorption of water-miscible vE and tocofersolan (Jacquemin E. et
al., J Clin Pharm & Ther 2009). Tocofersolan was well tolerated and represents a
liquid preparation of vE adapted to younger CF patients, with growing interest due
to generalisation of neonatal screening.
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Background: Majority of cystic ﬁbrosis (CF) patients are vitamin D insufﬁcient.
No evidence of beneﬁt or harm of vitamin D supplementation exists in the
CF population. Intervention trials are necessary, which require baseline data on
vitamin D status at the respective latitude.
Objective: To assess the vitamin D status in all CF patients living in Stockholm
region (n = 133; 59º 20′ North latitude), its development over 2007–2009 and
seasonal variation.
Methods: Descriptive statistics, independent t-test and univariate linear regression
were used to determine and compare serum 25-hydroxyvitamin D (s25OHD) levels,
seasonal variation (summer: May-Oct; winter: Nov-Apr) and vitamin D insufﬁciency
(s25OHD <75 nmol/L) prevalence.
Results: Over the years 2007–2009, the number of measurements of s25OHD
increased, whereas mean measured s25OHD remained stable (52.5; 52.7 and
51.3 nmol/L). Each year, 78−80% measured values were below the lower sufﬁciency
level. In 2009, more measurements were done in winter (61.5 vs. 44.6 and 44.1%;
p = 0.017 and p = 0.009). Mean s25OHD from measurements done in summer
(n = 150; 60.2 nmol/L) was higher than those from winter (n = 157; 44.3 nmol/L),
p< 0.001. Vitamin D insufﬁciency prevalence was lower during summer season
(68.0% vs. 89.8%; p< 0.001). Summer season explained 9% and 7% of variation
in s25OHD and vitamin D insufﬁciency.
Conclusion: Without coordinated intervention, vitamin D status of CF patients
does not change. Summer season is associated with better vitamin D status, but it
explains only a minor part of its variation. Majority of Stockholm CF patients have
insufﬁcient s25OHD levels both in winter and in summer.
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Recent UK Cystic Fibrosis (CF) guidelines have recommended that serum 25-OH
Vitamin D (25-OHD) levels should be maintained at 75–150 nmol/L to improve
bone accretion and so prevent bone disease and low bone mineral density.
A previous review of 25-OHD levels in 2003−4 showed that only 11 patients
(6%) had levels >75 nmol/L, mean(SD) 48(18) nmol/L. Our current practice is to
prescribe a daily Vitamin D supplement to all pancreatic insufﬁcient children of
10 ug per day, and following our previous review we implemented a more aggressive
regime where the Vitamin D supplement is incrementally increased up to 50 ug daily
if there is a persistently low serum 25-OHD.
Aim: To determine the prevalence of Vitamin D deﬁciency in our CF population,
in response to the more aggressive management adopted and our perception that
25-OHD levels >75 nmol/L may still not be achieved with this regimen.
Methods: Retrospective interrogation of our CF database for 25-OHD levels of
children attending for annual review in 2007, 2008 and 2009.
Results: See the table. The 2009 results were signiﬁcantly better (p< 0.001) than
either 2007 or 2008 (ANOVA).
Serum 25-OHD levels
Result available, N Mean (SD) >75nmol/L, N (%) <25nmol/L, N (%)
2007 107 50 (17.1) 9 (8) 4 (4)
2008 131 51.7 (25.3) 17 (13) 14 (11)
2009 122 65.7 (30.2) 45 (37) 10 (8)
Conclusion: Although, the proportion of children in our clinic with 25-OHD levels
in the recommended range is increasing, a signiﬁcant number remain below the
recommended range. Our current supplementation regimen will need to be reviewed
again to improve this further.
The question still remains: are serum 25-OHD levels >75 nmol/L achievable in all
our population?
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Background: CF Trust guidelines state that vitamin D supplementation should
be individualised with the aim of achieving serum 25-OH vitamin D (25OHD)
between 30 and 60mcg/L (CF Trust, 2007). We aimed to achieve recommended
25OHD levels by prescribing high dose vitamin D for patients who had levels
<30mcg/L.
Method: CF patients have their 25OHD levels checked annually and those with
levels <30mcg/L were given colecalciferol (vitamin D3) 100,000 units weekly for
6 weeks and levels rechecked after completion of the course (average 12.4 weeks).
Results: A total of 60 patients were given a course of high dose vitamin D between
Aug 2008 and Dec 2009 (mean pre-course 25OHD level = 12.3mcg/L).
Of these, 43 patients had a 25OHD level checked at the end of the course (mean
post-course 25OHD level = 32.8mcg/L). 42/43 patients had an increase in 25OHD
levels and one patient’s level remained the same (<5mcg/L).
20/43 patients achieved levels of >30mcg/L and of these 17 achieved the target
levels of 30−60mcg/L as recommended by the CF Trust. 3 patients had lev-
els >60mcg/L.
A total of 14 patients had levels rechecked at a later date (average 27 weeks after
starting vitamin D course). Most patients’ levels had decreased, but 6/14 remained
at 30−60mcg/L and all remained higher than their pre-course levels.
Conclusions: High dose vitamin D (as colecalciferol) is effective at increasing
25OHD levels in CF patients (mean pre level 12.3mcg/L; mean post level 32.8d
mcg/L). However, only 40% of patients achieved the CF Trust recommended level.
Although levels decreased with time, they were still higher than baseline after an
average of 27 weeks.
